Haeggquist & Eck, LLP Is Investigating Claims Against Regeneron Pharmaceuticals, Inc.’s Directors and Officers for Breach of Fiduciary Duty

SAN DIEGO--(BUSINESS WIRE)--Haeggquist & Eck, LLP, a leading shareholder rights litigation firm, is investigating whether certain directors and officers of Regeneron Pharmaceuticals, Inc. (“Regeneron”) (NASDAQ: REGN) breached their fiduciary duties to Regeneron and its shareholders. If you are a Regeneron shareholder, you are encouraged to contact Amber Eck at Haeggquist & Eck for additional information.

Haeggquist & Eck is investigating whether members of Regeneron’s Board of Directors or senior management failed to manage Regeneron in an acceptable manner, in breach of their fiduciary duties to Regeneron, and whether Regeneron has suffered damages as a result.

In January 2017, Regeneron received a subpoena from the U.S. Attorney’s Office for the District of Massachusetts regarding violations of federal anti-kickbacks statutes concerning use of patient-assistance funds to encourage doctors to prescribe certain of Regeneron’s drugs over less-expensive competitors.

In September 2019, Regeneron received a civil investigative demand from the U.S. Department of Justice pursuant to the federal False Claims Act investigating separate violations of federal anti-kickback statutes.

On June 24, 2020, federal prosecutors in Massachusetts filed suit against Regeneron, claiming violations of federal anti-kickback statutes.

What You Can Do

If you are a Regeneron shareholder, you may have legal claims against its directors and officers. If you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Amber Eck at 619-342-8000 or e-mail her at [e-mail]. There is no cost or obligation to you.

Haeggquist & Eck, LLP is a nationally recognized leader in shareholder rights law. The firm represents individual investors in shareholder derivative lawsuits, and members of the firm have helped shareholders recover more than $1 billion of value for themselves and the companies in which they have invested.

This release constitutes attorney advertising. Past results do not guarantee a similar outcome.